INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is an irreversible condition characterized by a progressive decline in lung function. 1 Being the fifth leading cause of death worldwide, it is mainly caused by tobacco exposure. 2 Other potential risk factors include exposure to outdoor pollution, occupational dust, and biomass fuels used for cooking. 3 Inhalation of cigarette smoke (CS) essentially leads to activation of epithelial cells, macrophages, and other innate immune cells including invariant natural killer T cells. 4, 5 The chronic inflammatory response progressively leads to airway remodelling, 6 increased mucus production, 7 and parenchymal destruction in the lungs, 8 further culminating in irreversible airflow limitation. Consequently, COPD patients are more susceptible to bacterial or viral airway infections. These respiratory infections are the principal cause of acute exacerbations, which invariably scarred the chronic course of COPD. 9 Airway colonization with bacteria such as Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae contributes to the pathogenesis and clinical course of the disease. 10 Non-typeable Haemophilus influenzae (NTHi) 11 not only colonizes the lungs of COPD patients during clinically stable periods, but acquisition of these bacteria is the most important cause of COPD exacerbations. 12 NTHi is a Gram-negative coccobacillus that lacks a polysaccharide capsule. It colonizes the upper respiratory tract of up to 75% of healthy adults and primarily acts as a mucosal pathogen. NTHi infections induce inflammation with prominent release of cytokines and chemokines including interleukin (IL)-1b, IL-6, tumor necrosis factor (TNF)-a, and CXCL1. In this setting, activation of Toll-like receptor-4 and -2 is important to trigger effective innate immune response to NTHi. Though NTHi is a well-recognized respiratory pathogen in COPD patients, 13 there is little information on the mechanisms and the susceptibility factors involved in COPD exacerbations. Bacterial infection during COPD (both in patients and experimental models) is characterized by an increased influx of immune cells, including neutrophils, 14 macrophages, 15 dendritic cells (DCs), 16 conventional CD8 þ T cells, 17 and NKT lymphocytes, 5 although the immune response is not able to eliminate the pathogens. Among factors involved in the control of the bacterial infection, the IL-17 cytokine family is crucial to elicit an effective host response, 18 although its potential role during NTHi infection is still unknown. IL-17A and the frequently associated cytokine IL-22 are key cytokines for the clearance of various pathogens including Gram-negative bacteria. 19 Among potential mechanisms, both cytokines induce the recruitment of neutrophils and the production of anti-microbial peptides, such as defensin-b, REG-3 proteins, or S100A9 by epithelial cells 14, 20 and other host defense genes. In the current study, we hypothesized that an altered production of Th17 cytokines might be responsible for reduced bacterial clearance and COPD exacerbation induced by NTHi. We show that mice chronically exposed to CS have an impaired ability to produce IL-22, but not IL-17, following challenge with NTHi. As showed in vitro, this might be related to a direct effect of CS exposure. Using Il22 À / À mice, we report an important role for IL-22 in host defense against NTHi. Finally, we show that IL-22 supplementation in COPD and Il22 À / À mice restored bacterial clearance and limited lung damages. Collectively, this study pinpoints the potential interest of targeting IL-22 to treat COPD exacerbation induced by respiratory bacteria.
RESULTS

COPD mice are more susceptible to NTHi infection
We have previously established that COPD features, including chronic inflammation, lung function decline, and mild emphysema, were induced in mice exposed to CS for 12 weeks. 5 Mice chronically exposed to CS were intranasally challenged with NTHi to trigger COPD exacerbation (Figure 1a) . At the dose used, NTHi induced a comparable weight loss in CS-exposed and air-exposed mice, with a peak at 3 days post infection (p.i.) (Figure 1b) . All mice recovered their initial body weight by day 7. Compared with control, COPD mice exhibited higher bacterial counts in bronchoalveolar lavage fluids (BALs) and lungs 24 and 48 h p.i. and then, the bacteria were rapidly cleared ( Figure 1c and not shown). The delay in bacterial clearance observed in COPD mice was not associated with a defective expression of anti-microbial peptides such as defensin-b2-3, LL-37, Reg-3g, Reg-3b, and S100A9 (not shown) as assessed by quantification of transcript. At the protein level, infection with NTHi increased the concentrations of S100A9 but not REG-3g and defensin-b2 and there was no difference between control and COPD mice (P ¼ NS) (Supplementary Figure S1 online).
Histological analysis of lung sections (Figure 1d) revealed that, at 24 h p.i., there was a moderate cell recruitment both in peribronchial, perivascular spaces, and in the alveoli of control mice. At 48 h, the inflammation was lower in the controls and no airway and alveolar remodeling could be evidenced. In COPD mice, NTHi infection induced a greater inflammation in all lung compartments inducing a severe alveolitis marked by alveolar wall thickening. This was also associated with vasculitis and more mucus secretion within the airways (Figure 1d ) at 48 h. This is confirmed by a significant difference between the histological scores (5.8 ± 0.8 vs. 7.2 ± 0.8 in control and COPD mice, respectively, at day 2). Although the inflammation and the alveolitis were resorbed in infected control mice, COPD mice still exhibited a strong thickening of the alveolar wall at day 7 post NTHi challenge, whereas the bacteria were no more detectable (not shown).
Altogether, these data demonstrate that COPD mice are more susceptible to NTHi infection and display increased lung inflammation and remodeling.
NTHi exposure triggers a greater inflammation in COPD mice
As COPD mice exhibited increased bacterial load and enhanced lung inflammation in response to NTHi, relative to control mice, we next characterized immune cells in the lungs and BALs of each group. At 24 h p.i., we observed an increased total cell number in the BALs and lungs of infected COPD mice, compared with controls ( Figure 2a) . The nature and the activation status of inflammatory cells were analyzed by flow cytometry as shown in the Supplementary Figure S2 . In contrast with alveolar macrophage, an increased number of DCs (Po0.05) and a trend for a higher neutrophil number in the BALs and lungs was reported in infected COPD mice compared with control mice (Figure 2a, b) . This increase was consistent at 48 h p.i. for neutrophils (P ¼ 0.02) (not shown). The number of inflammatory monocytes was also significantly increased at 48 h p.i. in BALs and lungs of COPD infected mice compared with control mice (data not shown). Infection with NTHi in COPD mice induced a more potent activation of BAL and lung DC, as shown by the greater expression of CD86 and I-Ab (Figure 2b) .
Moreover, we showed a significantly higher recruitment of both NKT and T cells in the BALs of infected controls and COPD mice (P ¼ 0.001) but not in the lungs (Figure 2c ). Higher levels of CD69 expression (Figure 2d) but not of CD25 (not shown) were observed in NKT cells from the BALs in both control and COPD infected mice compared with not-infected mice, whereas CD69 expression in conventional T lymphocytes was only increased by NTHi in the lung. Although not significant, there is a trend for an increased level of CD69 in NKT from infected COPD mice compared with controls. In contrast, the recruitment of NK cells tend to be lower in infected COPD mice (not shown).
Overall, increased susceptibility to NTHi infection in COPD mice cannot be explained by a defect in the recruitment and/or the activation of innate and adaptative immune cells.
CS-exposed mice infected with NTHi shows an impaired expression of IL-22
Inflammatory (IL-1b, IL-6, IL-23, and TNF-a) and immunomodulatory (IL-10, IL-13, IL-17, IL-22, and IFN-g) cytokines were upregulated after infection with NTHi in the BALs and lung lysates of control mice at 24 and 48 h p.i.. In COPD mice 24 h p.i., with the exception of IFN-g, significantly higher levels of IL-17 (Figure 3a) , IL-1b, IL-6, and TNF-a Figure S3 and not shown). Of interest, although both at 24 and 48 h, the infection with NTHi significantly increased the concentrations of IL-22 in BALs and lung tissue lysates of control mice, these levels were lower in infected COPD animals ( Figure 3a) .
To analyze the capacity of inflammatory cells to produce immunomodulatory cytokines, lung mononuclear cells were Figure S3 and not shown) p.i. In infected COPD mice, higher levels of IFN-g, IL-17 (Figure 3c ), IL-13, and TNF-a (not shown) were detected compared with the controls (Po0.05 for IFN-g and IL-17). In contrast, the levels of IL-22 were significantly lower in both unstimulated and HK-NTHi stimulated lung cells at 24 and 48 h as compared with controls ( Figure 3c) .
In order to identify which cells are deficient in the production of IL-22, we analyzed lung cells by intracellular flow cytometry after 3 h re-stimulation with phorbol 12-myristate 13-acetate and ionomycin. The percentage of IFN-g þ and IL-17 þ T and NKT cells did not differ in infected COPD mice compared with controls. In contrast, the number of IL-22 þ T cells in COPD mice was lower than in controls, whereas there was no difference in IL-22 þ NK and NKT cells in the lungs (Figure 3d and Supplementary Figure S4) .
In order to define the impact of CS exposure on the IL-22 production, spleen mononuclear cells were restimulated in vitro with HK-NTHi in the presence or not of CS extract (CSE). The activation with HK-NTHi significantly augmented the production of IL-17 and IL-22 in mononuclear cells (Figure 4) . Whereas the levels of IL-17 were higher in supernatants from NTHi-activated mononuclear cells of COPD mice compared with control mice, the levels of IL-22 were lower (Po0.05). As expected, exposure to CSE markedly reduced the concentrations of IL-22 (by 70-80%, Po0.05) in comparison with controls ( Figure 4b) . IL-17 levels were not modified by exposure to CSE. As CSE contains several ligands of aryl hydrocarbon receptor (AhR), a nuclear factor involved in the control of IL22 gene, we tested in parallel the effect of a canonical ligand of AhR, benzo[a]pyrene (B[a]P). Our data showed that addition of B[a]P did not alter IL-22 secretion in spleen cells, in contrast to CSE.
Altogether, these data showed that CS exposure specifically impairs the expression of IL-22.
IL-22 participates in host defense and in the maintenance of the lung structure during NTHi infection Our data suggest that IL-22 might be implicated in lung defense against NTHi. To investigate this further, Il22 À / À mice and wild-type (WT) mice were challenged with NTHi ( Figure 5a ). As shown in Figure 5b , IL-22-competent animals cleared the bacteria within 24 h, whereas IL-22-deficient animals had a delayed capacity to do so. In parallel, similar S100A9 and REG3g mRNA and protein levels were observed in the lungs of Il22 À / À mice and control mice, whereas the defensin-b2 was only upregulated in IL-22
À / À mice (Supplementary Figure S5) . In addition, the number of neutrophils was not significantly different in the lung of infected Il22 À / À mice, relative to WT counterparts (Figure 5c ). Histological analysis showed that the inflammation was almost solved by 48 h in WT mice, while the infiltrate was still present around the bronchi and alveoli in Il22 À / À mice (Figure 5d ). Moreover, alveolar wall thickening was also noticed in infected Il22 À / À mice but not in controls as illustrated by the histological score (6.2±0.37 and 4±0.32, respectively).
To confirm the role of IL-22, we supplemented IL-22
mice with recombinant murine (rm) IL-22 before infection (Supplementary Figure S6) . Intratracheal injection of rmIL-22 strongly amplified the bacterial clearance in BALs and lungs in IL-22 À / À mice (Supplementary Figure S6B) . Moreover, this treatment in infected IL-22 À / À mice slightly increased the concentrations of REG3g but not S100A9 and defensin-b2 (Supplementary Figure S7) . Supplementation with rmIL-22 markedly decreased neutrophil recruitment in lung but not in BALs from infected IL-22
À / À mice 24 h p.i. (Supplementary Figure S6D) .
These results suggest that IL-22 has an important role in host defense and in the maintenance of the lung structure during NTHi infection.
Supplementation with IL-22 blocks the development of NTHi-induced exacerbation in COPD mice
To confirm the role of IL-22 in COPD exacerbation induced by NTHi, we supplemented COPD mice with rmIL-22 before infection (Figure 6a) . Intratracheal injection of rmIL-22 strongly amplified the bacterial clearance in BALs and lungs from COPD mice (Figure 6b) . Moreover, this treatment increased the expression of S100A9 in the BALs of both groups, whereas REG-3g was only upregulated in the control mice and defensin-b2 was not modulated (Supplementary Figure S8 ). Treatment with rmIL-22 markedly decreased neutrophil recruitment (Po0.05) in infected COPD mice 24 h p.i., whereas it did not in control mice (Figure 6c) . Histopathological analysis confirmed that infected COPD mice exhibited higher cell recruitment within the lung at 24 and 48 h p.i., compared with control mice. As previously shown, infected COPD mice exhibited the features of pneumoniae with alveolitis and a strong vasculitis at 48 h (Figure 6d) . Treatment with rmIL-22 prior to infection markedly reduced the inflammatory infiltrate as well as the lesions targeting blood vessels and alveolar walls in COPD mice as confirmed by the histopathologic score (7 ± 0.41 vs. 4.33±0.31 in phosphate-buffered saline-and rmIL-22-treated COPD mice, respectively, Po0.05).
To measure the therapeutic effect of IL-22, we supplemented COPD mice with rmIL-22 6 and 18 h p.i. Intratracheal injection Preventive supplementation with rmIL-22 amplified the clearance of NTHi in COPD mice and limited lung damages resulting from infection.
DISCUSSION
There is evidence suggesting that COPD is projected to become one of the leading causes of death worldwide. The progression of COPD is worsened by lower airway infection mostly due to respiratory infection by NTHi. Here, we demonstrated that the cytokine response to NTHi was amplified in COPD mice with the marked exception for IL-22. Moreover, we showed that IL-22 is an essential factor in the control of infection by NTHi both in control and COPD mice.
To establish an acute model of exacerbation, mice chronically exposed to CS and presenting the characteristics of COPD 5 were challenged with NTHi. We observed an increased bacterial load in the lungs of COPD mice compared with control animals. These higher bacterial counts were associated with marked lung damage and increased mucus secretion. 21 Our data confirmed that NTHi significantly exacerbated the CS-induced damage. Though the inflammation and the alveolitis was resorbed in air-infected mice, the alveolitis and the pneumoniae was still prominent in infected COPD mice with a strong thickening of the alveolar wall persisting during at least 7 days. This observation was corroborated by higher influx of inflammatory cells including neutrophils and DC in COPD mice compared with control mice. COPD is often described as a neutrophilic inflammation. Neutrophils through the release of several proteases are involved in lung damages. 22 The increased presence of neutrophils in lung from COPD mice was probably associated with increased levels of IL-1b, IL-6, TNF-a, and IL-17 compared with control mice. 23 These cytokines participate in recruitment and activation of inflammatory cells in COPD lung. While IL-1b and TNF-a causes a release of inflammatory chemokines and metalloproteases from macrophages and epithelial cells in COPD lungs, 24 IL-6 is implicated in neutrophil chemotaxis. 23, 25 IL-17A also induces the production of neutrophil chemoattractants CXCL1 and CXCL8. 25, 26 The implication of IL-17A in the recruitment of neutrophils has been recently reported during NTHiinduced COPD exacerbation. 27 Altogether, neutrophils promote the lung inflammation and are probably implicated in the airway remodeling observed in infected COPD mice. As the inflammation exists before the infection and persists after the clearance of the bacteria in COPD mice, this recruitment results from both the COPD status and the infection and is not strictly related to the bacterial load.
Though the role of DC during COPD is not clearly understood, previous studies have shown an increased DC infiltration in small airways of COPD patients related to disease severity. 28 In our model of exacerbation, we observed a significantly higher DC number at 24 h post NTHi infection in smoke-exposed mice compared with air-exposed mice. These recruited DCs were activated at the site of inflammation as shown by the increased expression of CD86 and I-Ab 5 as well as in alveolar macrophages 29 and probably, participate at the inflammatory process in COPD. Together, these inflammatory cells seem to cause an irreversible breakdown of lung tissue characteristic of COPD probably through the activation of lymphocytes. 5 The activation of APC associated with the increased production of IL-1b and IL-6 in the lung, probably explains the presence of a significantly high number of T lymphocytes and the increased production of cytokines including IFN-g and IL-17 in the lung of COPD mice. Interestingly, neutralization of IL-17 during NTHi-induced COPD exacerbation reduced the neutrophil mobilization within the lung but did not modulate the bacterial clearance. 26 This suggests that controlling the inflammatory reaction associated with bacteria-induced exacerbation did not allow to restore an efficient IL-22 production and the elimination of the bacteria.
Interestingly, we detected a marked defect in IL-22 production in COPD mice challenged with NTHi. IL-22 has a crucial role in the defense against lung infections with Gram-negative bacteria. 20 We have recently observed an altered IL-22 response to S. pneumoniae during COPD both in murine model and in human patients. 30 With NTHi, we observed an altered production of IL-22 in conventional T lymphocytes but not in NK and NKT cells from infected COPD mice compared with control mice. As mentioned above, this defect is not related with an impaired activation of DC function nor to a defect in the production of pro-Th17 cytokines but is probably linked to an intrinsic defect in the development of Th22 cells. Interestingly, direct exposure to CSE alters the IL-22 production induced by HK-NTHi but not IL-17. We also tested the effect of B[a]P, a component of CS and a well-known ligand of AhR, a nuclear factor involved in IL-22 response. 31 Treatment with the AhR ligand did not decrease the production of IL-22 even in cells from COPD mice. These data suggest that exposure to CS directly inhibits the NTHi-induced production of IL-22 (but not IL-17) in an AhR-independent manner.
Regarding its role in anti-bacterial defense, IL-22 regulates the antimicrobial activity of lung epithelium, production of chemokines, and survival of Th17 cells. 32, 33 In our study, the level of anti-microbial peptides was not different between control and COPD mice. However, if we relate these levels to the bacterial load, we can suppose that these concentrations are not sufficient in order to control the infection in CS and Il-22 À / À mice. Moreover, supplementation with rmIL-22 increases the expression of anti-microbial peptides including S100A9 and REG-3g and at the same time, accelerates the clearance of NTHi. Interestingly, the defective production of IL-22 was associated with an increased dissemination of bacteria in both COPD and Il-22 À / À mice suggesting that IL-22 may also act through the modulation of the epithelial barrier function as previously reported during viral infection. 34 
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À / À mice challenged with NTHi also presented a weak alteration of neutrophil recruitment associated with a marked effect on bacterial load. Surprisingly, a similar profile was reported in COPD mice treated by rmIL-22. Both models differed by the higher cytokine burst in COPD mice. Treatment with rmIL-22 in COPD mice limits the development of the lung inflammatory reaction (including neutrophil influx) and the remodeling of the airways, a process probably related to the accelerated bacterial clearance. It remains to determine whether the action of IL-22 is linked to the promotion of anti-bacterial peptides, the priming of effector cell (including neutrophil), and/or the maintenance of the barrier function. As we are able to only demonstrate a preventive effect of IL-22 supplementation in our acute model, additional experiments using a more chronic model of infection are required to define the potential curative application of this treatment.
Altogether, we show that defective IL-22 production is involved in COPD exacerbation triggered by NTHi infection. This study identifies IL-22 as a therapeutic target to limit the consequences of NTHi infection in COPD. Restoration of an efficient bacterial clearance and a limitation of the inflammatory reaction could be a step forward for the treatment of COPD exacerbation. À / À mice of both sexes, 6-8 weeks old were purchased from Janvier Labs (Le Genest-St-Isle, France) or Jean-Christophe Renauld lab (Brussels, Belgium), respectively. WT mice were daily exposed to CS during 12 weeks. 5 The sham group was exposed to ambient air. Research cigarettes 3R4F were obtained from the University of Kentucky Tobacco and Health Research Institute (Lexington, KY). After 12 weeks of CS or air exposure, mice were either treated with phosphate-buffered saline or NTHi (2.5 Â 10 6 CFU; i.n.) (n ¼ 4 per group). All procedures were performed according to the Pasteur Institute, Lille, Animal Care and Use Committee guidelines (agreement number N 0 AF16/20090) and were approved by the local ethic committee. Experiments were performed at least in triplicate.
Preparation of bacteria and mice infection. NTHi strain 3224A was grown to log-phase in brain-heart infusion broth (AES Laboratoire, Marcy l'Etoile, France) supplemented with haematin and nicotinamide adenine dinucleotide (Sigma, St Louis, MO). The bacterial dose was checked by plating serial dilutions of broth cultures onto chocolate agar plates. For preparation of HK-NTHi), bacteria were grown to a log-phase (OD 600 nm ¼ 0.7-0.8 units) and incubated at 56 1C for 1 h in a water bath. Broth cultures were then plated onto chocolate agar plates and incubated overnight to check bacterial inactivation.
Mice were anesthetized and then intranasally challenged with 2.5 Â 10 6 colony-forming units (CFU) of NTHi. In IL-22 supplementation studies, 5 mg of rmIL-22 was administrated intranasally 24 h before and 6 h and 18h after NTHi challenge to demonstrate the prophylactic and therapeutic effect of IL-22.
Sample collection and processing. Mice were killed at 24 and 48 h p.i. BAL fluids, lungs, spleen, and blood were collected and kept on ice till the processing or immediately frozen in liquid nitrogen.
BAL samples were used for cytokine analysis, flow cytometry analysis, and numbering of CFUs. Lung tissues were collected aseptically and analyzed for CFU counts, cytokine analysis, pulmonary cell analysis (flow cytometry analysis and lung cell restimulation), and histology. Spleens were collected aseptically for flow cytometry analysis and restimulation culture analysis. Blood was used for the determination of CFU counts and cytokine analysis on serum. Levels of S100A9, Defb2, and REG3g were quantified in lung tissue lysates and BALs using commercial ELISA kits (Boster, Pleasanton, CA; Abbexa, Cambridge, UK).
Primers. Quantitative RT-PCR was performed to quantify mRNA of interest ( Table 1) . Results were expressed as mean±s.e.m. of the relative gene expression calculated for each experiment in folds (2 À DDCt ) using GAPH as a reference, and compared with controls.
Histological analysis. To study lung remodeling post-infection with NTHi, the lungs were inflated and fixed in formalin. The lungs were paraffin-embedded; cross-sections were cut and stained with hematoxylin and eosin. Histopathologic score was defined as described in Supplementary Information. SUPPLEMENTARY MATERIAL is linked to the online version of the paper at http://www.nature.com/mi
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